AU2018236353B2 - Methods of treating lysosomal disorders - Google Patents

Methods of treating lysosomal disorders Download PDF

Info

Publication number
AU2018236353B2
AU2018236353B2 AU2018236353A AU2018236353A AU2018236353B2 AU 2018236353 B2 AU2018236353 B2 AU 2018236353B2 AU 2018236353 A AU2018236353 A AU 2018236353A AU 2018236353 A AU2018236353 A AU 2018236353A AU 2018236353 B2 AU2018236353 B2 AU 2018236353B2
Authority
AU
Australia
Prior art keywords
leu
ser
val
ala
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018236353A
Other languages
English (en)
Other versions
AU2018236353A1 (en
Inventor
Eric Adler
Stephanie CHERQUI
Sylvia Evans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of AU2018236353A1 publication Critical patent/AU2018236353A1/en
Application granted granted Critical
Publication of AU2018236353B2 publication Critical patent/AU2018236353B2/en
Priority to AU2024201797A priority Critical patent/AU2024201797A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Environmental Sciences (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
AU2018236353A 2017-03-15 2018-03-15 Methods of treating lysosomal disorders Active AU2018236353B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024201797A AU2024201797A1 (en) 2017-03-15 2024-03-20 Methods of treating lysosomal disorders

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762471741P 2017-03-15 2017-03-15
US62/471,741 2017-03-15
US201762507713P 2017-05-17 2017-05-17
US62/507,713 2017-05-17
PCT/US2018/022598 WO2018170239A1 (en) 2017-03-15 2018-03-15 Methods of treating lysosomal disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024201797A Division AU2024201797A1 (en) 2017-03-15 2024-03-20 Methods of treating lysosomal disorders

Publications (2)

Publication Number Publication Date
AU2018236353A1 AU2018236353A1 (en) 2019-09-26
AU2018236353B2 true AU2018236353B2 (en) 2023-12-21

Family

ID=63523990

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018236353A Active AU2018236353B2 (en) 2017-03-15 2018-03-15 Methods of treating lysosomal disorders
AU2024201797A Pending AU2024201797A1 (en) 2017-03-15 2024-03-20 Methods of treating lysosomal disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024201797A Pending AU2024201797A1 (en) 2017-03-15 2024-03-20 Methods of treating lysosomal disorders

Country Status (8)

Country Link
US (2) US11806367B2 (https=)
EP (1) EP3596111A4 (https=)
JP (3) JP7233375B2 (https=)
CN (1) CN110418800A (https=)
AU (2) AU2018236353B2 (https=)
CA (1) CA3056617A1 (https=)
IL (1) IL269082A (https=)
WO (1) WO2018170239A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3056617A1 (en) 2017-03-15 2018-09-20 The Regents Of The University Of California Methods of treating lysosomal disorders
KR102918544B1 (ko) 2018-07-12 2026-01-27 로켓 파마슈티컬스, 리미티드 다논병을 치료하기 위한 유전자 요법 벡터
CN109880849B (zh) * 2019-01-03 2023-04-11 四川大学 靶向肿瘤相关巨噬细胞的GHOST-shRNA表达载体复合物及其应用
WO2020160458A1 (en) 2019-02-01 2020-08-06 Avrobio, Inc. Compositions and methods for treating neurocognitive disorders
WO2020179931A1 (ja) * 2019-03-07 2020-09-10 国立大学法人 東京医科歯科大学 ハイスループット遺伝子編集技術
US12319928B2 (en) * 2019-03-21 2025-06-03 The Regents Of The University Of Colorado, A Body Corporate Methods of treating Danon disease
WO2020210218A1 (en) * 2019-04-12 2020-10-15 The Regents Of The University Of California Methods for treating inherited eye defects
WO2021073607A1 (en) * 2019-10-17 2021-04-22 Westlake Therapeutics (Hangzhou) Co. Limited Engineering red blood cells for treatment of lysosomal storage diseases
GB202003536D0 (en) * 2020-03-11 2020-04-29 Ucl Business Ltd Gene therapy
US12173304B2 (en) * 2020-07-08 2024-12-24 Neuracle Genetics Inc. Intron fragments
CN114934066B (zh) * 2022-04-28 2024-10-18 深圳临研医学有限公司 石骨症的基因编辑体系及其应用
CN118388623B (zh) * 2024-06-28 2024-10-08 首都医科大学 Sialin蛋白在调控细胞线粒体功能中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014011237A1 (en) * 2012-07-11 2014-01-16 Sangamo Biosciences, Inc. Methods and compositions for the treatment of lysosomal storage diseases
WO2017003792A1 (en) * 2015-07-01 2017-01-05 The Regents Of The University Of California Retroviral vectors containing a reverse orientation human ubiquitin c promoter

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015529466A (ja) 2012-09-14 2015-10-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 鎌状赤血球症の幹細胞遺伝子治療のためのレンチウイルスベクター
HK1208371A1 (en) 2012-10-09 2016-03-04 桑比欧公司 Methods and compositions for treatment of retinal degeneration
US10155794B2 (en) 2013-07-16 2018-12-18 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of disorders related to CEP290
CN106459995B (zh) 2013-11-07 2020-02-21 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
US10670862B2 (en) 2015-07-02 2020-06-02 Microsoft Technology Licensing, Llc Diffractive optical elements with asymmetric profiles
JP7089282B2 (ja) * 2015-07-20 2022-06-22 アンジオクライン・バイオサイエンス・インコーポレイテッド 幹細胞移植のための方法および組成物
CA3056617A1 (en) 2017-03-15 2018-09-20 The Regents Of The University Of California Methods of treating lysosomal disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014011237A1 (en) * 2012-07-11 2014-01-16 Sangamo Biosciences, Inc. Methods and compositions for the treatment of lysosomal storage diseases
WO2017003792A1 (en) * 2015-07-01 2017-01-05 The Regents Of The University Of California Retroviral vectors containing a reverse orientation human ubiquitin c promoter

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Cox, T. 'Innovative Treatments for Lysosomal Diseases', Best Practice & Research Clinical Endocrinology & Metabolism, (2015-01-24), vol. 29, no. 2, pages 275 - 311,doi: 10.1016/J.BEEM.2015.01.001 *
Harrison, F. et al., 'Hematopoietic stem cell gene therapy for the multisystemic lysosomal storage disorder cystinosis', Molecular Therapy, (2013-02-01), vol. 21, no. 2, pages 433 - 444, doi:10.1038/mt.2012.214. *
Perez, L. et al., 'LAMP-2C Inhibits MHC Class II Presentation of Cytoplasmic Antigens by Disrupting Chaperone-Mediated Autophagy', The Journal of Immunology, (2016-01-07), vol. 196, no. 6, pages 2457-2465, doi:10.4049/jimmunol.1501476. *
Zhou, D. et al., 'Lamp-2A Facilitates MHC Class II Presentation of Cytoplasmic Antigens', Immunity, (2005), vol. 22, pages 571-581, doi: 10.1016/j.immuni.2005.03.009. *

Also Published As

Publication number Publication date
JP2020511470A (ja) 2020-04-16
EP3596111A1 (en) 2020-01-22
IL269082A (en) 2019-11-28
US20240009247A1 (en) 2024-01-11
EP3596111A4 (en) 2021-01-06
AU2024201797A1 (en) 2024-04-11
CA3056617A1 (en) 2018-09-20
AU2018236353A1 (en) 2019-09-26
JP2023052475A (ja) 2023-04-11
CN110418800A (zh) 2019-11-05
US11806367B2 (en) 2023-11-07
WO2018170239A1 (en) 2018-09-20
US20210161966A1 (en) 2021-06-03
JP7233375B2 (ja) 2023-03-06
JP2025039642A (ja) 2025-03-21

Similar Documents

Publication Publication Date Title
US20240009247A1 (en) Methods of treating lysosomal disorders
JP7399866B2 (ja) ＣＡＲＴｙｒｉｎ組成物とその利用方法
US20210189342A1 (en) Compositions and methods for modulating monocyte and macrophage inflammatory phenotypes and immunotherapy uses thereof
JP2021507703A (ja) Ｖｃａｒ組成物とその利用法
JP2020532987A (ja) キメラリガンド受容体（ｃｌｒ）介在性の条件遺伝子発現のための組成物および方法
JP6761113B2 (ja) キメラ抗原受容体
CN116059245A (zh) 治疗线粒体障碍的方法
JP6960396B2 (ja) 分裂終了細胞の細胞分裂を誘発するための方法
CN108602873A (zh) 工程化抗原呈递细胞及其用途
KR20220139926A (ko) 인공 시냅스
KR20230160823A (ko) 치료 전달을 위한 조성물 및 방법
KR20230148824A (ko) 핵산을 전달하기 위한 조성물 및 방법
KR20240005837A (ko) 성숙한 각막 내피 세포의 생성 방법
CN117642187A (zh) 用于治疗听力损失的基因疗法构建体和方法
BR112019014406A2 (pt) métodos de tratar esclerose múltipla usando células t autólogas
KR20230002681A (ko) 대형 아데노바이러스 페이로드의 통합
KR20220057596A (ko) 동종이계 세포 조성물 및 사용 방법
HK40016634A (en) Methods of treating lysosomal disorders
JP2022524419A (ja) 最適化されたｒａｇ１欠損遺伝子治療
CN110639012A (zh) 一种能有效治疗和/或预防1型糖尿病的dna疫苗及其用途
EP2265636B1 (en) Mzb1, a novel b cell factor, and uses thereof
AU2026202687A1 (en) Compositions and methods for modulating monocyte and macrophage inflammatory phenotypes and immunotherapy uses thereof
US20220177918A1 (en) Methods for treating inherited eye defects
HK40126591A (zh) 通用t细胞和组合物及它们的使用方法
EP4426726A1 (en) Compositions and methods for treating interleukin 7 receptor deficiency

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)